RefleXion Medical announced today that the first patient completed treatment with Scintix biology-guided radiotherapy on its X1 machine.
Scintix treats early- and late-stage cancers using the individual biology of each tumor to drive its own treatment. It allows each cancer’s unique biology to autonomously determine how much radiation to deliver. This occurs on a second-by-second basis during the actual treatment delivery. The radiotherapy treatment received FDA clearance in February of this year.
The first completed treatment took place at Stanford Medicine Cancer Center.
“We are elated that Stanford Medicine is the first healthcare provider to deliver Scintix treatment, marking the first delivery of autonomous radiotherapy,” said Sam Mazin, founder and CTO of RefleXion.“We have been working toward this milestone for over a decade, and on behalf of everyone at RefleXion, I want to thank our early adopter clinical sites, numerous advisors, and our investors for working alongside us to develop and bring to market this new option for patients with all stages of solid tumors.”
More about the RefleXion Scintix treatment
Scintix’s initial FDA clearance enabled biology-guided radiotherapy for patients with lung and bone tumors. These tumors may arise from primary cancers or metastatic lesions spread from other cancers in the body. Before that, the therapy held FDA breakthrough device designation for treating lung tumors.
The treatment uses emissions from cancer cells created by injecting the patient with a radiopharmaceutical. It delivers a radiation dose that continuously and autonomously targets the cancer itself. This fundamental capability simultaneously lights up all indicated cancer targets in the body during treatment.
RefleXion said X1 with Scintix is the only dual-treatment modality radiotherapy platform for treating solid tumors of any stage.
In the coming weeks, the company expects specific cancer centers in California, Pennsylvania and Texas to begin offering Scintix therapy. By the end of 2023, RefleXion intends to offer availability in New Jersey, Connecticut, and Oregon, too.
“This first Scintix treatment is a watershed moment for physicians and patients alike because finally, we have a technology with the potential to meet the challenges of treating metastatic disease head-on,” said Todd Powell, president and CEO of RefleXion. “Clinical literature and emerging practice guidelines are beginning to incorporate the importance of treating all visible disease in certain cancers. Scintix was conceived with that end in mind, and to work in combination with drug therapies to improve outcomes, especially for patients with advanced-stage cancers.”